Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA Business Segments

Income StatementBalance SheetCash FlowRatiosSegments
QuarterlyAnnualTTM
YoYQoQ
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Revenue by Product
Amtagvi$236.68M+60.9%$220.02M+112%$203.84M—$188.39M—$147.14M—
Proleukin$48.93M-25.3%$43.48M-28.1%$46.59M+29.4%$53.13M+166%$65.54M+3,342%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Iovance Biotherapeutics, Inc. break its business down?
Iovance Biotherapeutics, Inc. (IOVA) reports revenue by product across 2 parts — Amtagvi and Proleukin. Each is extracted from the segment footnotes and tracked over time.
Where does Iovance Biotherapeutics, Inc.'s segment data come from?
Segment breakdowns are pulled from the segment footnotes in Iovance Biotherapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.